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ABSTRACT
Background: Although survival has improved in recent decades, the short-term prognosis of patients
with immunoglobulin light chain (AL) amyloidosis remains grim. We aimed to assess overall survival
(OS) of AL amyloidosis patients by comparing cohorts in two consecutive time periods.
Methods: Data were collected and compared on 126 patients from two tertiary referral centres in The
Netherlands during the time periods 2008–2012 and 2013–2016.
Results: There was a non-significant trend to improved 6-month OS in the last cohort (78% vs. 67%,
p¼ .216, crude odds ratio 1.66, 95%CI 0.74–3.70, adjusted odds ratio 2.22, 95%CI 0.88–5.56). Patients
in this cohort had higher Mayo risk scores (stage III 40% vs. 24%, p< .001 and revised stage IV 14%
vs. 11%, p< .001), higher use of bortezomib (50% vs. 30%), and better haematological response (com-
plete response/very good partial response in 39% vs. 27%, p< .001). Diagnostic delay was similar in
both time periods.
Conclusions: In the 2013–2016 cohort there was a trend toward improved 6-month OS, and an
improved haematological response. Patients in this cohort had more advanced cardiac disease and
received bortezomib more frequently, but diagnostic delay was similar to the 2008–2012 cohort. For
further prognostic improvement, practitioners should be more alert, especially for cardiac amyloidosis.
Abbreviations: AL: amyloid light chain; ASCT: autologous stem cell transplantation; BMPC: bone mar-
row plasma cells; BNP: B-type natriuretic peptide; CR: complete response; dFLC: difference between
involved and uninvolved free light chains; FLC: free light chains; HDM: high dose melphalan; IMiD’s:
immunomodulatory imide drugs; NT-proBNP: N-terminal proBNP; OS: overall survival; PR: partial
response; SD: stable disease; UMC: University Medical Centre; VGPR: very good partial response
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Systemic immunoglobulin light chain (AL) amyloidosis is char-
acterized by aggregation and deposition of monoclonal
immunoglobulin free light chains (FLC) in several tissues, lead-
ing to organ dysfunction. Clinical manifestations and outcomes
depend on the extent of organ involvement. Cardiac involve-
ment in particular has a major negative impact on prognosis.
Another negative prognostic factor is a delay between start of
symptoms and the diagnosis, because these patients present
with more advanced organ damage [1–3].
The short-term prognosis of AL amyloidosis depends
greatly on the extent of cardiac involvement. Biomarkers of
heart failure and cardiac injury, such as B-type natriuretic
peptide (BNP) or N-terminal proBNP (NT-proBNP) and
troponins T or I are therefore used for risk assessment and
monitoring. The long-term prognosis of patients with AL
amyloidosis depends on haematological response after treat-
ment and on overall organ involvement. The latter is related
to the on-going supply of involved FLCs to the tissues.
Consequently, serum FLCs, and especially the difference
between the involved and uninvolved FLC (dFLC), can also
be used for risk assessment and monitoring [4–6].
Therapy used for the treatment of multiple myeloma has
been shown to be effective in AL amyloidosis as well [7]. New
developments in treatment modalities for multiple myeloma
have also changed treatment of the far less common AL amyl-
oidosis [8]. The introduction of high dose melphalan (HDM)
followed by autologous stem cell transplantation (ASCT) led
to a better haematological response and organ response in AL
amyloidosis patients [9]. Over the years, the treatment-related
mortality of this procedure has declined, likely due to better
patient selection [10]. However, most patients are not eligible
for ASCT. Recently, proteasome inhibitors such as bortezomib
and immunomodulatory imide drugs (IMiD’s) such as thal-
idomide and lenalidomide have become available [7,11]. A
recently published study conducted in the Mayo Clinic
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showed that the introduction of melphalan-dexamethasone
and bortezomib-based therapy as first-line therapy has con-
tributed to improved overall survival (OS). This study, which
included 1551 patients, showed an improvement of the short-
term prognosis: 6month OS increased from 63% in cohort
2000–2004 to 76% in cohort 2010–2014 (p< .001).
Nevertheless, short-term mortality remained high [11].
Until the 1980s, survival of patients with AL amyloidosis
in the Netherlands was very poor, with a median OS of
7months. This was primarily because the vast majority of
patients had been left untreated [12]. This improved to a
median OS of 12months in patients diagnosed between
1990 and 2003, who were treated with prednisone and mel-
phalan or HDM followed by ASCT [13]. However, more
recent outcomes of patients with systemic AL amyloidosis
in the Netherlands are unknown. We therefore evaluated
126 AL amyloidosis patients who were diagnosed between
2008 and 2016 in two tertiary referral centres for amyloid-
osis in the Netherlands, and compared the last cohort
(2013–2016) with the first cohort (2008–2012).
Methods
Patients
We retrieved information on 186 patients who were diag-
nosed with systemic AL amyloidosis at the University
Medical Centre Utrecht (UMC Utrecht) and the University
Medical Centre Groningen (UMC Groningen). At the UMC
Groningen the registry started in 2008 and at the UMC
Utrecht in 2012. Patients were eligible for inclusion if diag-
nosed with systemic AL amyloidosis and treated at either
centre between January 1 2008 and December 31 2016. Of
the 186 patients, 48 patients were not eligible because they
fell outside the scope of our study: seven patients were diag-
nosed in an earlier time period; in five patients the diagno-
sis of amyloidosis was uncertain; 35 patients were seen for a
second opinion and were treated elsewhere; and one patient
who received stem cell therapy was sent back immediately
afterwards to the referring hospital. Of the remaining 138
eligible patients with AL amyloidosis, 12 (8.7%) were lost to
follow-up, thus leaving 126 patients for analysis. We divided
these patients into two cohorts based on the year of diagno-
sis; 2008–2012 (cohort I) including 46 patients, and period
2013–2016 (cohort II) including 80 patients.
In all included cases, amyloidosis was diagnosed by positive
Congo red staining of tissue retrieved using a screening fat tis-
sue aspirate or targeted organ biopsy. Systemic involvement
was confirmed by another biopsy from a different organ or tis-
sue, or by the combination of clinical features typical for amyl-
oidosis in an organ or tissue other than that from which a
biopsy with a positive Congo red stain was obtained. Amyloid
type AL was preferably demonstrated by a positive anti-kappa
or anti-lambda light chain staining using immunohistochemis-
try in combination with a definitely negative staining for amyl-
oid type amyloid A (AA) and amyloid transthyretin (ATTR).
In addition, increased production of either kappa or lambda
FLC had to be present. Diagnostic delay was defined as the
time between the first documented signs or symptoms of AL
amyloidosis and the date that amyloid had been diagnosed by
biopsy. Both organ involvement and haematological response
were based on consensus criteria [6,14]. Haematological
response categories are complete response (CR), very good par-
tial response (VGPR), partial response (PR), stable disease (SD)
and progression. At UMC Utrecht, the cardiac biomarkers
BNP and troponin I were measured, while at UMC Groningen,
NT-proBNP and troponin T were used. Based on these cardiac
biomarkers, both the Mayo 2004 and 2012 staging system crite-
ria were applied [4,5]. For bone marrow plasma cell percentage,
the highest estimated percentage was used. Treatment was cate-
gorized as ASCT after high-dose or intermediate-dose melpha-
lan, melphalan-dexamethasone (MDex), bortezomib-based
regimen, IMiD-based regimen, single-agent dexamethasone or
“other treatment”. The latter category included treatment com-
monly used for Waldenstr€om’s macroglobulinemia: rituximab
monotherapy or rituximab in combination with chlorambucil
or dexamethasone and cyclophosphamide.
Data analysis
The v2 test was used to compare differences between nom-
inal and ordinal variables, and the one-sample t-test and
the independent-samples t-test were used to compare
means between groups. Kaplan–Meier analysis was used
for survival analysis. Besides our own data, in the analysis
we used historical data on overall survival of systemic
amyloidosis previously reported in The Netherlands
[12,13]. Only patients with AL amyloidosis were included
in the analysis. OS was calculated using time from diagno-
sis to last follow-up or death. Due to the short follow-up
in the most recent cohort, median OS was not expected to
be reached. In addition we determined 6-month OS and
2-year OS. The 6-month follow-up was available for all
patients, but the 2-year follow-up only for 25% of patients.
The majority of these missing data points were from the
2013-2016 cohort, because the 2 year follow-up of part of
this cohort has not yet taken place. To compare the 6-
month OS of the two cohorts (2008–2012 vs. 2013–2016),
we used a multivariate analysis in line with a previous
study [11], with adjustment for age, gender and variables
related to severity of disease (dFLC, number of bone mar-
row plasma cells (BMPC), number of organs involved and
heart involvement). To deal with missing values (six for
dFLC and 14 for BMPC) we did multiple imputation (5
times) before multivariate analysis and used pooled esti-
mated adjusted odds ratios with 95% confidence intervals.
Because data from UMC Utrecht was only available from
2012 onwards, we performed sensitivity analysis compar-
ing the results from UMC Utrecht and UMC Groningen
selectively from 2012 to 2016. Analyses were performed
with SPSS version 23.
Results
Baseline characteristics
The baseline characteristics are shown in Table 1. The mean
age at diagnosis was 64 years (range 45–82) and 57% of the
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patients were male. The mean time from start of complaints
to diagnosis was 14.7months (range 0–156months). This
delay did not decrease as the study progressed and was
14.0months in cohort I versus 14.9 in cohort II (p¼ .947).
The most common symptoms at diagnosis were oedema
(43.7%), dyspnoea (42.9%), fatigue (38.9%), weight loss
(33.3%), peripheral sensory neuropathy (27.0%), changed
defaecation pattern (22.2%), orthostatic hypotension (19.8%)
and bleeding tendency (15.1%). Four patients did not have
any complaints at diagnosis. The percentage of patients with
two or more organs involved did not differ between the two
cohorts and was 49% in cohort II and 39% in cohort I
(p¼ .491). Cardiac involvement was seen in 74% of patients
in both cohorts.
Lambda restricted light chains were found in 71% of the
patients and in 4 patients (5%) the light chain amyloidosis
was associated with Waldenstr€om’s disease. The median
dFLC was significantly higher in cohort II (16.9mg/dL in
cohort I and 18.2mg/dL in cohort II, p¼ .008). There was
no significant difference in mean BMPC percentage between
the cohorts (15% in cohort I and 12.5% in cohort
II, p¼ .107).
The cardiac biomarkers NT-proBNP, BNP, troponin I
and T were not always available in the data. As a result,
only 75% of the patients were staged by the Mayo 2004
staging system [4] and 63% by the revised Mayo 2012 stag-
ing system [5]. More patients had poorer prognoses in
cohort II; 40% of patients from cohort II were in Mayo
stage III compared to 24% from cohort I (p< .001), while
14% from cohort II were in revised Mayo stage IV com-
pared to 11% from cohort I (p< .001). Based on only highly
elevated NT-proBNP of >8500 ng/L, 13 patients in cohort I
and 14 patients in cohort II (p¼ .055) were classified as
very high-risk patients.
Treatment
In total, 109 patients (87%) were treated. The other 13% of
the patients did not receive treatment due to advanced dis-
ease or death before start of treatment. Patients received up
to five lines of treatment with a median of one line. In total,
48 different combinations of regimens were used as first-
line therapy and were grouped into five categories, which
are shown in Table 2. In the first line of treatment, the use
of bortezomib-based therapy increased from 30% in cohort
I to 50% in cohort II, whereas the use of IMiD-based ther-
apy decreased from 30% to 8%.
Table 1. Baseline characteristics of 126 AL amyloidosis patients, divided into two consecutive time periods.
Characteristic Both time periods (n¼ 126) Period 2008–2012 (n¼ 46) Period 2013–2016 (n¼ 80) p value
Mean age in years 63.9 64.1 63.8 .469
Age  65 years, n (%) 60 (48) 22 (48) 38 (48) .972
Male, n (%) 72 (57) 27 (59) 45 (56) .789
Organs involved, n (%)
>2 organs 57 (45) 18 (39) 39 (49) .296
Neurological 46 (37) 15 (33) 31 (39) .491
Heart 93 (74) 34 (74) 59 (74) .984
Liver 26 (21) 6 (13) 20 (25) .061
Renal 78 (62) 27 (59) 51 (64) .813
Gastro-intestinal tract 33 (26) 12 (26) 21 (26) .984
Lung 6 (5) 3 (7) 3 (4) .482
Soft tissue 33 (26) 13 (28) 20 (25) .689
Light chains
k restricted, n (%) 90 (71) 33 (72) 57 (71) .747
Unknown 1 0 1
Median dFLC in mg/dL 17.5 16.9 18.2 .008
Unknown 6 0 6
dFLC <0.5mg/dL, n (%) 3 (2) 0 (0) 3 (4) .062
dFLC  18mg/dL, n (%) 59 (49) 22 (48) 37 (46) .159
Mean BMPC in % 13.5 15.0 12.5 .107
Unknown 14 1 13
Brain natriuretic peptides
Unknown 8 2 6
Median NT-proBNP in ng/L 2100.5 2462.0 2100.5 .402
NT-proBNP  332 ng/L, n (%) 84 (82) 35 (46) 49 (61) .079
NT-proBNP  1800 ng/L, n (%) 54 (53) 21 (46) 33 (41) .071
BNP median, pg/mL 745 487.0 1139.0 .236
BNP  100 pg/mL, n (%) 23 (88) 4 (9) 19 (24) .036
Troponins
Unknown 19 4 15
Troponin I median, ng/L 0.04 0.00 0.05 .306
Troponin I  0,10lg/L, n (%) 7 (29) 0 (0) 7 (9) .045
Troponin T median, lg/L 0.032 0.00 0.048 .665
Troponin T  0,035lg/L, n (%) 38 (46) 11 (24) 27 (34) <.001
Troponin T  0.025 lg/L, n (%) 46 (55) 13 (28) 33 (41) <.001
Mayo AL amyloidosis 2004 stage, %
I/II/III/unknown 11/29/34/25 15/50/24/11 9/18/40/34 <.001
Mayo AL amyloidosis 2012 stage, %
I/II/III/IV/unknown 14/14/22/13/37 24/24/24/11/17 9/9/21/14/48 .002
dFLC: difference between the involved and uninvolved free light chains; BMPC: bone marrow plasma cells; BNP: B-type natriuretic peptides; NT-proBNP:
N-terminal proBNP. A p-value < 0.05 is considered bold significant.
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Overall, 25 patients (20%) received ASCT as first line of
treatment in both cohorts. In 23 out of 25 patients, ASCT
was preceded by induction therapy. In cohort I, ASCT was
preceded by IMiD-based induction therapy in 50% of the
patients and by bortezomib-based induction therapy in 30%
of the patients. In cohort II, IMiD-based induction therapy
was used in 23% of patients and bortezomib-based induc-
tion therapy in 75%.
Haematological response
The haematological response to first line of treatment
improved between the cohorts; CR/VGPR was reached in
27% in cohort I and 39% in cohort II (p< .001). In patients
who received ASCT, the percentage of patients who
achieved VGPR or CR was similar in both cohorts: 70% in
cohort I and 65% in cohort II (p¼ .521). Haematological
response data to first line of treatment was missing for 24%
of patients in cohort I and 28% in cohort II.
Survival
OS in our study was compared to survival in previous stud-
ies reported in The Netherlands (Figure 1(A)). The median
OS significantly improved over time: from 7months in
patients diagnosed between 1964–1985 to 12months in
patients diagnosed between 1990–2003 and to 53.5months
in patients in our study who were diagnosed between
2008–2016 (p< .001) [12,13].
The median OS was 52.5months for cohort I and
53.5months for cohort II (p¼ .503). The 6-month OS was
67% for cohort I and 78% for cohort II (OR 1.66 (95% CI
0.74–3.70), p¼ .216) and the 2-year OS was 60% for cohort
I and 66% for cohort II (p¼ .349). Survival by cohort is
shown in Figure 1(B). This OS curve suggests trend (non-
significant) towards improved survival in the most recent
cohort. The multivariate analysis for factors influencing 6-
month survival is shown in Table 3. After adjustment for
number of organs involved, heart involvement, dFLC and
BMPCs, the trend to improved survival remained, with a
higher point estimate (OR 2.22, 95% CI 0.88–5.56, p¼ .09).
Median OS was much higher in patients without cardiac
involvement (median OS was not reached in patients without
cardiac involvement compared to 42.1months for patients with
cardiac involvement, p¼ .005). This was also seen in the 6-
Figure 1. Survival from time of diagnosis per cohort. (A)Survival of historical
cohorts 1964–1985 12 and 1990–2003 13 versus complete current study cohort
2008–2016, p< .001. (B) Survival of cohort 2008–2012 versus cohort
2013–2016, p¼ .503.
Table 2. Treatment and haematological response of 126 AL amyloidosis patients, divided into two consecutive time periods.
Characteristic Both time periods (n¼ 126) Time period 2008–2012 (n¼ 46) Time period 2013–2016 (n¼ 80) p value
First line of treatment, n (%)
ASCT 25 (20) 9 (20) 16 (20) .045
MDex 3 (2) 1 (2) 2 (3)
Bortezomib-based 54 (43) 14 (30) 40 (50)
IMiD-based 20 (16) 14 (30) 6 (8)
- Lenalidomide 8 (6) 2 (4) 6 (8)
- Thalidomide 12 (10) 11 (24) 1 (1)
Single-agent dexamethasone 2 (2) 0 (0) 2 (3)
Others 5 (4) 2 (4) 2 (3)
No treatment 17 (13) 6 (13) 11 (14)
Haematological response to first line treatment (n5 110) (%)
Complete response 24 (22) 8 (20) 16 (23) <.001 .563
Very good partial response 14 (13) 3 (7) 11 (16)
Partial response 22 (20) 9 (22) 13 (19) –
Stable disease 17 (15) 8 (20) 9 (13)
Progression 4 (4) 3 (7) 1 (1)
Unknown 29 (26) 10 (24) 19 (28)
ASCT: autologous stem cell transplantation; MDex: melphalan dexamethasone; IMiD: immunomodulatory imide drugs.
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month OS (94% without cardiac involvement compared to
66% with cardiac involvement, p¼ .004) and the 2-year OS
(87% compared to 56%, p¼ .002). The survival curve of
patients with and without cardiac involvement in both cohorts
is shown in Figure 2(A). A trend to improved survival was
seen in patients presenting with fewer than two organs
involved (median OS of 56.8months with fewer than 2 organs
involved compared to 39.0months with 2 or more organs
involved, p¼ .075); 6-month OS, 81% compared to 66%,
p¼ .047; 2-year OS, 73% compared to 54%, p¼ .028). The
median OS was higher in patients with dFLC <18mg/dL than
in patients with dFLC 18mg/dL (median OS was not reached
in patients with dFLC <18mg/dL compared to a median OS of
11.47months in patients with dFLC >18mg/dL, p¼ .002), 6-
month OS 82% compared to 64% (p¼ .03) and 2-year OS 78%
compared to 49% (p< .001). The survival curve of patients
according to dFLC cut-off 18mg/dL is shown in Figure 2(B).
The Mayo 2004 and 2012 staging systems were both prognostic
for OS. The 6-month OS for patients with Mayo 2004 risk
score I was 100%, with II it was 78% and with III it was 53%
(p< .001); the 2-year OS for patients with these risk scores was
92%, 73% and 38% (p< .001), respectively. The 6-month OS
for patients with Mayo 2012 risk score I was 94%, with II it
was 89%, with III it was 57% and with IV it was 38%. The 2-
year OS for patients with these risk scores was 89%, 82%, 49%
and 31% (p¼ .002), respectively. The OS was also dependent
on the type of therapy patients received (p< .001). In patients
who received ASCT as the first line of treatment, 6-month OS
was 100% and 2-year OS was 91%. For patients who received
non-ASCT therapy, the median OS was 52.9months, the 6-
month OS was 75% and the 2-year OS was 67%. For the 13%
of patients who did not receive any treatment, the median OS
was 2.4months, the 6-month OS was 29% and the 2-year OS
was 10%.
Sensitivity analysis comparing results of the UMC
Utrecht and the UMC Groningen
The 6-month OS was 83% (25/30) at UMC Utrecht and
69% (45/65) at UMC Groningen. The 2-year OS was 67%
(20/30) at UMC Utrecht and 63% (41/65) at UMC
Groningen. A CR or VGPR in this time period was reached
in 59.1% of the patients at UMC Utrecht and 47.2% at
UMC Groningen (p¼ .38). Differences between the two
centres in OS and haematological response were not
significant.
Discussion
In this retrospective analysis of 126 AL amyloidosis patients
diagnosed and treated in the two expertise centres in The
Netherlands, we evaluated presentation, diagnostic delay,
treatment and outcome between 2008 and 2016 and com-
pared two patients cohorts (2008–2012 and 2013–2016).
The time between symptom onset and diagnosis was
similar in the two cohorts, with a median diagnostic delay
of 15months. This is similar to the results of a recent
patient survey, with a delay in diagnosis of more than one
year in 37.1% of the patients [15]. This median delay in
diagnosis is longer than previously reported. The Mayo
Clinic reported a delay of 10months, an Italian study
reported 6months, and a Chinese study reported 7months
[11,16,17]. Early diagnosis is crucial; it enables early treat-
ment intervention and may therefore prevent irreversible
organ damage and improve the prognosis [16]. Lousada
et al. stated that only 7.6% of the patients received the diag-
nosis of amyloidosis after visiting one physician, and that
31.8% visited 5 physicians before receiving the diagnosis
[15]. This suggests that the diagnosis of AL amyloidosis
should be considered more often by cardiologists, nephrolo-
gists, neurologists and haemato-oncologists. Although initia-
tives were undertaken in the Netherlands to improve
awareness among both lay people and physicians to reduce
diagnostic delay, such as the launch of a patient organiza-
tion in 2013 and the initiation of expert centres in 2015,
these efforts have not yet resulted in greater awareness and
earlier diagnosis. Therefore, improving the awareness of
medical specialists should still have high priority.
The total rate of cardiac involvement was similar in both
cohorts (74%), and was in line with other cohort studies
that reported rates between 53 and 76% [11,17,18].
Surprisingly, patients in the more recent cohort had even
more advanced cardiac disease with higher Mayo 2004 and
2012 risk scores. Moreover, in the more recent cohort a
higher (but not significantly higher) proportion of the
patients presented with two or more organs involved. Also,
the median dFLC was significantly higher in the more
recent cohort (18.2mg/dL versus 16.9mg/dL). This dFLC
value is another important prognostic factor, and is lower
than that reported in a study from the Mayo Clinic: a dFLC
of 23.7mg/dL [11].
It should be noted that our study was based on patients
referred to tertiary centres. Compared to other studies,
Table 3. Two models with adjusted odds ratios (OR) for 6-month overall survival in 126 AL amyloidosis patients.
Model 1 Adjusted OR (95% CI) p value Model 2 Adjusted OR (95% CI) p value
Cohort 2013-2016 2.17 (0.85–5.56) .106 2.22 (0.88–5.56) .091
Heart involvement 0.16 (0.03–0.78) .023 0.17 (0.04–0.81) .026
2 organs involved 0.42 (0.17–1.08) .069 0.43 (0.17–1.09) .074
BMPC  10% 0.99 (0.97–1.00) .102 0.99 (0.97–1.00) .100
dFLC per mg/dL 1.00 (0.99–1.00) .100 1.00 (0.99–1.00) .133
Age per year 0.97 (0.92–1.02) .256 – –
Female gender 0.74 (0.29–1.85) .512 – –
95% CI: 95% confidence interval; OR: odds ratio.
Cohort 2013–2016 was compared to cohort 2008–2012. The unadjusted or crude odds ratio was 1.66 (95% CI 0.74–3.70).
When adjusted for age, gender and variables related to severity of disease mentioned in Table 3, the odds ratio increased to
2.17 (95% CI 0.85–5.56) and when adjusted only for variables related to severity of disease, the odds ratio further increased
to 2.22 (95% CI 0.88–5.56).
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patients with more advanced disease may therefore be over-
represented. In a 2012 Swedish nationwide registration
study, the estimated incidence of AL amyloidosis was 3.2
per million inhabitants [19]. In The Netherlands, compris-
ing 17 million inhabitants, 55 newly-diagnosed patients with
AL amyloidosis per year would then be expected. In two of
our expertise centres, 186 patients were seen during 9 years,
or about 20 new patients per year on average. We therefore
analyzed approximately 40% of all cases of AL amyloidosis
in the Netherlands that were diagnosed from 2008 to 2016.
A factor that could have affected our study concerns the
new treatment options that have become available in recent
decades. In our study population, 13% of the patients did not
receive any treatment due to advanced disease or death before
start of treatment. This is a higher percentage than previously
reported in a study by the Mayo Clinic, in which 6%, 7% and
11% of the patients remained untreated in the time periods
2000–2004, 2005–2009 and 2010–2014 respectively [11]. In
our study and others reported in literature, in recent time
periods patients received bortezomib-based therapy more
often as first line treatment in the more recent time periods
[11] and in recent years induction therapy changed from
IMiD-based therapy to bortezomib-based therapy.
Importantly, these new treatment options led to significantly
improved haematological response in our study. In patients
who received first line treatment, the CR/VGPR rate was 27%
in the 2008–2012 cohort and 39% in the 2013–2016 cohort.
In a retrospective study at the Mayo Clinic, a much higher
CR/VGPR rate was reported (51% in 2000–2004, 58% in
2005–2009 and 66% in 2010–2014). This could be partly
explained by the higher ASCT rate in this selected Mayo
cohort, which was about one-third compared to 20% in our
cohort. In the Mayo cohort, patients who received ASCT had
the highest response rate (65% to 70%) and this figure
remained stable during the time period studied [11]. As
reported by D’Souza et al., not only haematological response
after ASCT improved over the years, but early mortality after
ASCT also declined between 1995 and 2012 [20].
In our analyses, a non-significant trend to improved 6-
month OS was seen in the more recent cohort (67% in the
2008–2012 cohort and 78% in the 2013–2016 cohort). The
point estimate of this trend was even better after adjustment
for variables related to severity of disease (dFLC, BMPCs,
number of organs involved and heart involvement) (crude
OR 1.66, 95% CI 0.74–3.70, adjusted OR 2.22, 95% CI
0.88–5.56). This effect is very likely the result of more
effective treatment over the years, even though patients in
the more recent cohort have more severe disease (higher
Mayo risk scores and dFLC). In line with our results, study
at the Mayo Clinic showed a statistically significant
improvement in 6-month OS from 63% in the 2000–2004
cohort to 76% in the 2010–2014 cohort [11].
Strengths and limitations
We analyzed treatment data for approximately 40% of the
total AL amyloidosis population in The Netherlands, that
was diagnosed between 2008 and 2016.
Limitations: In our study, 8.7% of patietns were lost to
follow up and we had missing values in some determinants
and in haematological response as shown in Table I. If miss-
ing values in haematological response data occured for dif-
ferent reasons in one cohort compared to the other and/or
were not completely random, this could bias the results by
either overestimating or underestimating the effect. Both of
Figure 2. Survival of subgroups in all 126 AL amyloidosis patients. (A) Cardiac
involvement versus no cardiac involvement in cohort I and II, p< .025. (B)
Difference between the involved and uninvolved free light chain <18mg/dL or
>18mg/dL in cohort I and II, p¼ .003.
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the above shortcomings are related to the use of routine
care data. Another limitation concerns patient follow-up.
Although all patients had 6months of follow up, a majority
(75%) had not yet completed two years of follow-up. Data
on 2-year OS should therefore be interpreted cautiously.
Finally, limitations are the retrospective nature of the study
and the relatively low number of outcomes.
Conclusion
By comparing the 2008–2012 and 2013–2016 cohorts we
showed an improvement in haematological response of AL
amyloidosis patients within the last decade. There was also a
trend towards improved 6-month OS. These favourable
findings are probably the result of improvements in anti
plasma cell treatment over the years. However, the delay in
diagnosis is still too high and patients in the most recent
cohort even presented with more advanced disease and
worse risk scores. To reduce the long diagnostic delay that
currently blocks further improvement in survival, awareness
of amyloidosis should be improved among cardiologists,
nephrologists, neurologists and other medical specialists.
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